Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: The Contempo Update on attention-deficit/hyperactivity
disorder (ADHD) by Dr Wilens and colleagues1 presented
pharmacologic treatment options. However, in discussing the use of stimulant
medications, the authors did not address risks of addiction, tolerance, or
habituation. I would like to know if the authors think that these risks are
significant enough to warrant having patients sign a treatment contract acknowledging
the risks and the conditions of ongoing care. I would also be interested in
whether they think patients receiving stimulant treatment should be evaluated
monthly in the office prior to refills and, if not, what other refill mechanisms
they would recommend.
Raphaelson M. Stimulants and Attention-Deficit/Hyperactivity Disorder. JAMA. 2004;292(18):2214. doi:10.1001/jama.292.18.2214-a